Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient

Hirota, Kazuyoshi; Kabara, Shizuko; Hashimoto, Hiroshi; Ishihara, Hironori; Matsuki, Akitomo

doi:10.1034/j.1399-6576.2001.045004510.x

Cited by 7 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine our hypothesis, after approval of our university ethical committee, we assessed the efficacy of olprinone, a PDEIII inhibitor for treatment of patients showing asthmatic attack under oral theophylline medication, by our direct visualization method using a superfine fiberoptic bronchoscope. Although we had only one case during the research period, we confirmed that olprinone could produce a potent bronchodilation and that this direct visualization method may be more sensitive to determine relaxant effects of olprinone than peak airway pressure [18] (Fig. 5).…”

Section: Application Of the Direct Visualization Methods To Clinical Psupporting

confidence: 78%

Study on airway smooth muscle tone using fiberoptic bronchoscopy: basic research and clinical application

Hirota

2010

J Anesth

View full text Add to dashboard Cite

Section: Application Of the Direct Visualization Methods To Clinical Psupporting

confidence: 78%

Study on airway smooth muscle tone using fiberoptic bronchoscopy: basic research and clinical application

Hirota

2010

J Anesth

View full text Add to dashboard Cite

“…Olprinone, a specific PDE III inhibitor, has been found to have inotropic and peripheral vasodilatory effects [4], [30]. It is well known that the substrate specificity of PDE III is cAMP > cGMP; therefore, PDE III inhibitors will increase the intracellular cAMP concentration [9]–[11].…”

Section: Discussionmentioning

confidence: 99%

Olprinone Attenuates the Acute Inflammatory Response and Apoptosis after Spinal Cord Trauma in Mice

et al. 2010

View full text Add to dashboard Cite

BackgroundOlprinone hydrochloride is a newly developed compound that selectively inhibits PDE type III and is characterized by several properties, including positive inotropic effects, peripheral vasodilatory effects, and a bronchodilator effect. In clinical settings, olprinone is commonly used to treat congestive cardiac failure, due to its inotropic and vasodilating effects. The mechanism of these cardiac effects is attributed to increased cellular concentrations of cAMP. The aim of the present study was to evaluate the pharmacological action of olprinone on the secondary damage in experimental spinal cord injury (SCI) in mice.Methodology/Principal FindingsTraumatic SCI is characterized by an immediate, irreversible loss of tissue at the lesion site, as well as a secondary expansion of tissue damage over time. Although secondary injury should be preventable, no effective treatment options currently exist for patients with SCI. Spinal cord trauma was induced in mice by the application of vascular clips (force of 24 g) to the dura via a four-level T5–T8 laminectomy. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, apoptosis, and locomotor disturbance. Olprinone treatment (0.2 mg/kg, i.p.) 1 and 6 h after the SCI significantly reduced: (1) the degree of spinal cord inflammation and tissue injury (histological score), (2) neutrophil infiltration (myeloperoxidase activity), (3) nitrotyrosine formation, (4) pro-inflammatory cytokines, (5) NF-κB expression, (6) p-ERK1/2 and p38 expression and (7) apoptosis (TUNEL staining, FAS ligand, Bax and Bcl-2 expression). Moreover, olprinone significantly ameliorated the recovery of hind-limb function (evaluated by motor recovery score).Conclusions/SignificanceTaken together, our results clearly demonstrate that olprinone treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.

show abstract

“…In this study we tested 1 and 10 µg·kg -1 ·min which produce bronchodilatation in humans 7 and in animals 8 were similar or smaller than the doses administered in this study.…”

Section: Responses Of Pial Arterioles To Olprinonementioning

confidence: 99%

“…[10][11][12][13] Recently, it also has been reported that olprinone has a bronchodilator effect, and that bronchial asthma may be treated by iv olprinone in humans 7 and animals, 8 and by inhalation of olprinone in humans.…”

Section: Responses Of Pial Arterioles To Olprinonementioning

confidence: 99%

“…5,6 Therefore, we aim to use bronchodilators that do not affect the hypoxia-induced cerebral vasodilatation. Recently, it was reported that olprinone, a phosphodiesterase III (PDE III) inhibitor, has a bronchodilator effect in human patients suffering an asthma attack, 7 and in dogs with bronchoconstriction induced by 5HT. 8 These reports suggest that olprinone could be a safe drug to use to treat severe asthma.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits

Miyabe

Tajima

Takahashi

et al. 2003

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

P Pu ur rp po os se e: : Olprinone, a phosphodiesterase III inhibitor, is used for the treatment of heart failure or asthma. Such patients may suffer from hypoxia. However, the effect of olprinone on the cerebral vasodilator response to hypoxia remains unclear.M Me et th ho od ds s: : Rabbits were anesthetized and ventilated mechanically. The pial arteriolar diameter was determined using a cranial window and intravital microscopy. Hypoxia was induced twice in the same animal by reducing FIO 2 to 0.1. The first episode was induced during an infusion of saline, and the second during an infusion of saline (saline group; n = 8) or olprinone (1 µg·kg , OLP10 group; n = 8). The pial arteriolar responses to hypoxia were recorded and compared between the two episodes of hypoxia in each group. R Re es su ul lt ts s: : Blood gas data in the first hypoxic challenge were identical to those in the second challenge in each group. Pial arteriolar diameter increased significantly during hypoxia. In arterioles between 50-100 µm diameter, first and second hypoxia-induced pial arteriolar dilatation in OLP1 were 13 ± 6% and 10 ± 7% respectively (P = 0.574 ) and those in OLP10 were 16 ± 6% and 15 ± 7% respectively (P = 0.606). In arterioles between 25-50 µm, the results were the same as in arterioles between 50-100 µm.C Co on nc cl lu us si io on n: : Olprinone does not affect the hypoxia-induced dilatation of pial arterioles in pentobarbital anesthetized rabbits. OLP1, de 13 ± 6 % et de 10 ± 7 % respectivement (P = 0,574 ) et dans le groupe OLP10, de 16 ± 6 % et de 15 ± 7 % respectivement ( P = 0,606 Objectif

show abstract

Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient

Cited by 7 publications

References 10 publications

Study on airway smooth muscle tone using fiberoptic bronchoscopy: basic research and clinical application

Study on airway smooth muscle tone using fiberoptic bronchoscopy: basic research and clinical application

Olprinone Attenuates the Acute Inflammatory Response and Apoptosis after Spinal Cord Trauma in Mice

Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits

Contact Info

Product

Resources

About